CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy.

Abstract excerpt

PURPOSE: Mavacamten is the first targeted therapy for obstructive hypertrophic cardiomyopathy (oHCM). It is metabolised via cytochrome p450 enzymes, with variations in the CYP2C19 gene having predominant influence on plasma concentrations of mavacamten. We aimed to outline the effect of CYP2C19 metaboliser status on outcomes in patients taking mavacamten. METHODS: We retrospectively analysed clinical and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Cardiomyopathy, Hypertrophic